Advances in Lipid Nanoparticles for mRNA-Based Cancer Immunotherapy

Abstract

Over the past decade, messenger RNA (mRNA) has emerged as potent and flexible platform for the development of novel effective cancer immunotherapies. Advances in non-viral gene delivery technologies, especially the tremendous progress in lipid nanoparticles’ manufacturing, have made possible the implementation of mRNA-based antitumor treatments. Several mRNA-based immunotherapies have demonstrated antitumor effect in preclinical and clinical studies, and marked successes have been achieved most notably by its implementation in therapeutic vaccines, cytokines therapies, checkpoint blockade and chimeric antigen receptor (CAR) cell therapy. In this review, we summarize recent advances in the development of lipid nanoparticles for mRNA-based immunotherapies and their applications in cancer treatment. Finally, we also highlight the variety of immunotherapeutic approaches through mRNA delivery and discuss the main factors affecting transfection efficiency and tropism of mRNA-loaded lipid nanoparticles in vivo.

References 97

1. 1.

   Arteta M. Y. Kjellman T. Bartesaghi S. Wallin S. Wu X. Kvist A. J. (2018 ). Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles. Proc. Natl. Acad. Sci. U.S.A. 115, E3351–E3360.

   Not in our library10.1073/pnas.1720542115

2. 2.

   Bailey A. L. Cullis P. R. (1994 ). Modulation of membrane fusion by asymmetric transbilayer distributions of amino lipids. Biochemistry 33, 12573–12580.

   Not in our library10.1021/bi00208a007

3. 3.

   Baldin A. V. Savvateeva L. V. Bazhin A. V. Zamyatnin A. A. Jr (2020 ). Dendritic cells in anticancer vaccination: rationale for ex vivo loading or in vivo targeting. Cancers 12:590

   Not in our library10.3390/cancers12030590

4. 4.

   Ball R. L. Hajj K. A. Vizelman J. Bajaj P. Whitehead K. A. (2018 ). Lipid nanoparticle formulations for enhanced co-delivery of siRNA and mRNA. Nano Lett. 18, 3814–3822.

   Not in our library10.1021/acs.nanolett.8b01101

5. 5.

   Belliveau N. M. Huft J. Lin P. J. C. Chen S. Leung A. K. K. Leaver T. J.. (2012 ). Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA. Mol. Ther. Nucleic Acids 1:e37.

   Not in our library10.1038/mtna.2012.28

6. 6.

   Billingsley M. M. Singh N. Ravikumar P. Zhang R. June C. H. Mitchell M. J. (2020 ). Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering. Nano Lett. 20, 1578–1589.

   Not in our library10.1021/acs.nanolett.9b04246

7. 7.
   Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA · 2019

   No notice
8. 8.

   Blanco E. Shen H. Ferrari M. (2015 ). Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 33, 941–951.

   Not in our library10.1038/nbt.3330

9. 9.

   Brudno J. N. Kochenderfer J. N. (2016 ). Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127, 3321–3330.

   Not in our library10.1182/blood-2016-04-703751

10. 10.

    Cheng Q. Wei T. Farbiak L. Johnson L. T. Dilliard S. A. Siegwart D. J. (2020 ). Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat. Nanotechnol. 15, 313–320.

    Not in our library10.1038/s41565-020-0669-6

11. 11.
    Immunosenescence and human vaccine immune responses · 2019

    No notice
12. 12.

    Cullis P. R. Hope M. J. (2017 ). Lipid nanoparticle systems for enabling gene therapies. Mol. Ther. 25, 1467–1475.

    Not in our library10.1016/j.ymthe.2017.03.013

13. 13.

    De Beuckelaer A. Pollard C. Van Lint S. Roose K. Van Hoecke L. Naessens T.. (2016 ). Type I interferons interfere with the capacity of mRNA lipoplex vaccines to elicit cytolytic T cell responses. Mol. Ther. 24, 2012–2020.

    Not in our library10.1038/mt.2016.161

14. 14.

    Eygeris Y. Patel S. Jozic A. Sahay G. (2020 ). Deconvoluting lipid nanoparticle structure for messenger RNA delivery. Nano Lett. 20, 4543–4549.

    Not in our library10.1021/acs.nanolett.0c01386

15. 15.
    Cancer immunotherapy: the beginning of the end of cancer? · 2016

    No notice
16. 16.

    Felgner P. L. Ringold G. M. (1989 ). Cationic liposome-mediated transfection. Nature 337, 387–388.

    Not in our library10.1038/337387a0

17. 17.

    Fenton O. S. Kauffman K. J. McClellan R. L. Appel E. A. Dorkin J. R. Tibbitt M. W.. (2016 ). Bioinspired alkenyl amino alcohol ionizable lipid materials for highly potent in vivo mRNA delivery. Adv. Mater. 28, 2939–2943.

    Not in our library10.1002/adma.201505822

18. 18.

    Foster J. B. Barrett D. M. Karikó K. (2019 ). The emerging role of in vitro-transcribed mRNA in adoptive T cell immunotherapy. Mol Ther. 27, 747–756.

    Not in our library10.1016/j.ymthe.2019.01.018

19. 19.

    Gall D. (1966 ). The adjuvant activity of aliphatic nitrogenous bases. Immunology 11, 369–386.

    Not in our library

20. 20.

    Gilleron J. Querbes W. Zeigerer A. Borodovsky A. Marsico G. Schubert U.. (2013 ). Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat. Biotechnol. 31, 638–646.

    Not in our library10.1038/nbt.2612

21. 21.
    Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives · 2020

    No notice
22. 22.

    Granot Y. Peer D. (2017 ). Delivering the right message: challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics-An innate immune system standpoint. Semin. Immunol. 34, 68–77.

    Not in our library10.1016/j.smim.2017.08.015

23. 23.

    Guan S. Rosenecker J. (2017 ). Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems. Gene Ther. 24, 133–143.

    Not in our library10.1038/gt.2017.5

24. 24.

    Guevara M. L. Jilesen Z. Stojdl D. Persano S. (2019a ). Codelivery of mRNA with α-Galactosylceramide using a new lipopolyplex formulation induces a strong antitumor response upon intravenous administration. ACS Omega 4, 13015–13026.

    Not in our library10.1021/acsomega.9b00489

25. 25.

    Guevara M. L. Persano S. Persano F. (2019b ). Lipid-based vectors for therapeutic mRNA-based anti-cancer vaccines. Curr Pharm Des. 25, 1443–1454.

    Not in our library10.2174/1381612825666190619150221

26. 26.

    Haabeth O. A. W. Blake T. R. McKinlay C. J. Tveita A. A. Sallets A. Waymouth R. M.. (2019 ). Local delivery of Ox40l, Cd80, and Cd86 mRNA kindles global anticancer immunity. Cancer Res. 79, 1624–1634.

    Not in our library10.1158/0008-5472.can-18-2867

27. 27.

    Hajj K. A. Whitehead K. A. (2017 ). Tools for translation: non-viral materials for therapeutic mRNA delivery. Nat. Rev. Mater. 2:17056

    Not in our library10.1038/natrevmats.2017.56

28. 28.

    Harper P. E. Mannock D. A. Lewis R. N. A. H. McElhaney R. N. Gruner S. (2001 ). X-ray diffraction of some phosphatidylethanolamine lamellar and inverted hexagonal phases. Biophys. J. 81, 2693–2706.

    Not in our library10.1016/s0006-3495(01)75912-7

29. 29.
    Clinical development of CAR T cells—challenges and opportunities in translating innovative treatment concepts · 2017

    No notice
30. 30.

    Henriksen-Lacey M. Christensen D. Bramwell V. W. Lindenstrom T. Agger E. M. Andersen P.. (2010 ). Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a cmi response. J. Control Release 145, 102–108.

    Not in our library10.1016/j.jconrel.2010.03.027

31. 31.
    How mRNA therapeutics are entering the monoclonal antibody field · 2019

    No notice
32. 32.

    Holtkamp S. Kreiter S. Selmi A. Simon P. Koslowski M. Huber C.. (2006 ). Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 108, 4009–4017.

    Not in our library10.1182/blood-2006-04-015024

33. 33.

    Islam M. A. Xu Y. Tao W. Ubellacker J. M. Lim M. Aum D. (2018 ). Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA. Nat. Biomed. Eng. 2, 850–864.

    Not in our library10.1038/s41551-018-0284-0

34. 34.

    Jackson H. J. Rafiq S. Brentjens R. J. (2016 ). Driving CAR T-cells forward. Nat. Rev. Clin. Oncol. 13, 370–383.

    Not in our library10.1038/nrclinonc.2016.36

35. 35.
    The promise of mRNA vaccines: a biotech and industrial perspective · 2020

    No notice
36. 36.

    Judge A. McClintock K. Phelps J. R. MacLachlan I. (2006 ). Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol. Ther. 13, 328–337.

    Not in our library10.1016/j.ymthe.2005.09.014

37. 37.
    Advances in the delivery of RNA therapeutics: from concept to clinical reality · 2017

    No notice
38. 38.

    Kaczmarek J. C. Patel A. K. Kauffman K. J. Fenton O. S. Webber M. J. Heartlein M. W.. (2016 ). Polymer-lipid nanoparticles for systemic delivery of mRNA to the lungs. Angew. Chem. Int. Ed. Engl. 55, 13808–13812.

    Not in our library10.1002/anie.201608450

39. 39.

    Karikó K. Muramatsu H. Ludwig J. Weissman D. (2011 ). Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res. 39:e142.

    Not in our library10.1093/nar/gkr695

40. 40.

    Kon E. Hazan-Halevy I. Rosenblum D. Cohen N. Chatterjee S. Veiga N.. (2020 ). Resveratrol enhances mRNA and siRNA lipid nanoparticles primary CLL cell transfection. Pharmaceutics 12:520.

    Not in our library10.3390/pharmaceutics12060520

Cited by papers we hold 7

• mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications · 2023
  No notice
• Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics · 2023
  No notice
• Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects · 2022
  No notice
• mRNA-based therapeutics: powerful and versatile tools to combat diseases · 2022
  No notice
• mRNA vaccines for cancer immunotherapy · 2022
  No notice
• A Survey of Preclinical Studies Evaluating Nanoparticle-Based Vaccines Against Non-Viral Sexually Transmitted Infections · 2021
  Not checked
• A novel mechanism for the loss of mRNA activity in lipid nanoparticle delivery systems · 2021
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.